Skip to content

Acupuncture treatment based on sensitive points for Irritable bowel syndrome with diarrhea : a randomised controlled trial

Acupuncture treatment based on sensitive points for Irritable bowel syndrome with diarrhea : a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074179
Enrollment
Unknown
Registered
2023-08-01
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome with diarrhea

Interventions

High sensitive group:Subjects were treated with acupuncture at five highly sensitive (lowest pain threshold) acupoints. Sterile, disposable millimeters needles of 40 mm in length and 0.30 mm in diamet
Low sensitive group:Subjects were treated with acupuncture at five lowly sensitive (highest pain threshold) acupoints. Sterile, disposable millimeters needles of 40 mm in length and 0.30 mm in diamete
Waiting for treatment group:Subjects will not receive any acupuncture during the study. Due to ethical considerations, we will provide free, non-investigational standard acupuncture treatment upon com

Sponsors

Affiliated Hospital of Jiangxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet IBS-D diagnostic criteria; (2) Age 18-65 years; (3) A total IBS-SSS score of =75 at baseline; (4) Had not used any medication for IBS for at least 2 weeks before treatment and had not received acupuncture for IBS-D in the last 3 months; (5) Voluntarily participated in the study by signing an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with organic lesions of the intestinal tract, or systemic diseases that affect the function of the digestive tract; (2) Those who have a combination of serious primary diseases such as cardiovascular system, liver, kidney, hematopoietic system, psychiatric disorders, and significant cognitive dysfunction; (3) Those with a history of abdominal or rectal-anal surgery; (4) Pregnant, lactating, postpartum women = 12 months and those with allergies; (5) Those with metal allergy or severe fear of needles; (6) Participating in other clinical trials, which will affect the observation of efficacy indicators; (7) Those who refuse to sign the informed consent and violate the trial program. Note: Anyone with any of the above conditions should be excluded.

Design outcomes

Primary

MeasureTime frame
IBS Symptom Severity Scale;

Secondary

MeasureTime frame
IBS Specialized Quality of Life Scale;Bristol Fecal Characterization Scale;

Countries

China

Contacts

Public ContactJiang fan

Affiliated Hospital of Jiangxi University of Chinese Medicine

jiangfanky@outlook.com+86 173 4666 6303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026